scholarly journals Evolutionary Insights into the “Population-Specificity” of the Genetic Factors Associated with Inflammatory Bowel Diseases

10.5772/27317 ◽  
2012 ◽  
Author(s):  
Shigeki Nakagome ◽  
Hiroki Oot
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Genetic Factors ◽  
Factors Associated ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Tu1296 Non-Economic Factors Associated With Medication Adherence in Inflammatory Bowel Diseases. It's as Complex as the Individual Patient

2012 ◽  
Vol 142 (5) ◽  
pp. S-796
Author(s):  
Edel McDermott ◽  
Denise Keegan ◽  
Cara Dunne ◽  
Aoibhlinn M. O'Toole ◽  
Kathryn Byrne ◽  
...  
Keyword(s):  
Medication Adherence ◽  
Inflammatory Bowel Diseases ◽  
Economic Factors ◽  
Factors Associated ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
The Individual

scholarly journals Genetic factors in pathogenesis, course and treatment of inflammatory bowel diseases

2015 ◽  
Vol 69 ◽  
pp. 335-344 ◽  
Author(s):  
Hubert Zatorski ◽  
Maciej Sałaga ◽  
Marta Zielińska ◽  
Jakub Fichna
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Genetic Factors ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals AB0484 TROUGH LEVELS OF TNF-Α INHIBITORS AND THEIR IMMUNOGENICITY IN THE TREATMENT OF RHEUMATIC DISEASES AND INFLAMMATORY BOWEL DISEASES

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 1269.2-1270
Author(s):  
T. Nuriakhmetova ◽  
I. K. Valeeva ◽  
J. Shevnina ◽  
D. Abdulganieva
Keyword(s):  
Rheumatic Diseases ◽  
Inflammatory Bowel Diseases ◽  
Trough Level ◽  
Certolizumab Pegol ◽  
Factors Associated ◽  
Low Level ◽  
Tnf Α ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Trough Levels

Background:The features of the underlying immune-mediated disease can affect the efficacy, pharmacokinetics and immunogenicity of the biologic agents, which are among the important predictors of loss of response to TNF-α inhibitors (TNFi).Objectives:To compare the frequency of TNFi low trough levels and their immunogenicity in the treatment of rheumatic diseases (RD) (ankylosing spondylitis (AS) and rheumatoid arthritis (RA)) and inflammatory bowel diseases (IBD) (Crohn’s disease (CD) and ulcerative colitis (UC)).Methods:Among 120 patients (40 with AS (33.3%), 19 with RA (15.8%), 42 with CD (35%), and 19 with UC (15.8%)), trough level of infliximab (INX) (n=36, 30%), adalimumab (ADM) (n=45, 37.5%) and certolizumab pegol (CZP) (n=39, 32.5%) and the level of anti-drug antibodies (ADAb) were measured in the serum samples drawn directly before the planned drug administration.Results:Low drug level (below 0.5 μg/mL for INX1, 4.9 µg/ml for ADM2, and 20 µg/l for CZP3) was found in 54 (45%) patients: in 33 (55.9%) patients with RD and 21 (34.4%) patients with IBD. In the RD group, low drug trough level was observed more often than in IBD (55.9% vs 34.4%, OR 2.418, 95% CI 1.157 to 5.052, p=0.018). Only in UC was there a relationship between the received low dose of the drug (up to 200 mg of INX, 40 mg of ADM, and 200 mg of CZP) and its low level in the serum (p=0.026). Among the additional factors associated with a low TNFi level, lower dose of concomitant therapy at the time of a biologic initiation (66.7% vs 20.8%, OR 7.6, 95% CI 1.388 to 41.617, p=0.033) and the absence of pseudopolyps (78.9% vs 21.1%, p=0.045) were found in IBD, and in case of RD these factors included the age of 30 to 45 years (72.7% vs 41.9%, OR 3.692, 95 % CI 1.136 to 12.0, p=0.026), the absence of comorbidities (58.6% vs 41.4%, OR 3.44, 1.09 to 10.858, p=0.032) and male gender (78.8% vs 50% in women, OR 3.714, 95% CI 1.194 to 11.552, p=0.02).ADAb were detected in 29 (24.2%) patients (7 to INX (19.4%), 8 (17.8%) to ADM, 14 (35.9%) to CZP), 23 (79.3%) of which had also a concomitant low trough level of the drug. There were no significant differences in the frequency of ADAb formation between the pathologies. In the AS group, antibodies to CZP were detected in all patients with a low level of the biologic, while only in 25% of patients receiving ADM, a low level was associated with the formation of ADAb (p=0.019). In addition, among patients with AS, ADAb were detected only in those patients who did not take prednisone at the time of blood serum sampling (100% vs 37.9%, p=0.037).Conclusion:Low level of TNFi is more common in RD than in IBD. For each group, the factors associated with a low trough level of TNFi were identified. There were no significant differences in the frequency of ADAb formation between nosologies.References:[1]Steenholdt C, Bendtzen K, Brynskov J, et al. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn’s disease. Scand J Gastroenterol 2011; 46: 310–318.[2]Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, Dijkmans BA, Aarden L, Wolbink GJ. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305:1460–1468. doi: 10.1001/jama.2011.406.[3]Gehin, J.E., Goll, G.L., Warren, D.J. et al. Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study. Arthritis Res Ther 21, 256 (2019). https://doi.org/10.1186/s13075-019-2009-5Disclosure of Interests:Tatiana Nuriakhmetova Grant/research support from: A grant to purchase reagents for scientific research from Novartis Pharmaceuticals, Ildariya Khairullovna Valeeva: None declared., Jana Shevnina: None declared., Diana Abdulganieva: None declared.

scholarly journals Does Drinking Coffee and Tea Affect Bone Metabolism in Patients with Inflammatory Bowel Diseases?

Nutrients ◽  
2021 ◽  
Vol 13 (1) ◽  
pp. 216
Author(s):  
Alicja Ewa Ratajczak ◽  
Aleksandra Szymczak-Tomczak ◽  
Agnieszka Zawada ◽  
Anna Maria Rychter ◽  
Agnieszka Dobrowolska ◽  
...  
Keyword(s):  
Bone Metabolism ◽  
Inflammatory Bowel Diseases ◽  
Genetic Factors ◽  
Lower Bone Mineral Density ◽  
Mineral Density ◽  
Bowel Diseases ◽  
Other Substances ◽  
Inflammatory Bowel ◽  
Diet Level ◽  
Affect Bone Metabolism

Patients suffering from Crohn’s disease and ulcerative colitis are at higher risk of osteoporosis due to lower bone mineral density. Risk factors of osteoporosis are divided into unmodifiable, namely, age, gender, genetic factors, as well as modifiable, including diet, level of physical activity, and the use of stimulants. Coffee and tea contain numerous compounds affecting bone metabolism. Certain substances such as antioxidants may protect bones; other substances may increase bone resorption. Nevertheless, the influence of coffee and tea on the development and course of inflammatory bowel diseases is contradictory.

Sign in / Sign up

Export Citation Format

Share Document